Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Moderna, Inc.NASDAQ: MRNA

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development declines year over year

Q3 FY2026 research & development of $583M fell 27.2% year over year, behind the -23.6% change in trailing-twelve-month research & development. Sequentially, it fell 10.4% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Research & development amounted to 161.1% of revenue in FY2025, up 19.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.2% toward the trailing-twelve-month pace of -23.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$583M-10.4% QoQ
Last fiscal yearDec 2025
$3.13B-31.1% YoY
LTMSep 2026
$2.66B-23.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.2%——
1 year-31.1%——
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.13B USD
Year-over-year change
-31.1%
4-year CAGR
+12.0%

Research & Development vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.6% is the 8th highest of 10, against a peer median of -0.6%.
  • Research & development amounts to 105.3% of revenue for MRNA, versus a peer median of 57.9%.
MRNA Competitors
Research & Development for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M USD-27.2%-33.9%—
Peer median (excluding MRNA) —-0.6%-3.0%57.9%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.